Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Bedaquiline-containing regimens show sustained benefit in rifampicin-resistant TB

Bedaquiline-containing regimens show sustained benefit in rifampicin-resistant TB

16 Oct 2024 bởiJairia Dela Cruz

In the treatment of patients with rifampicin-resistant tuberculosis (TB), two bedaquiline-containing regimens, namely a 9-month all-oral regimen and a shorter 6-month regimen with 8 weeks of aminoglycoside, maintains superior efficacy to a 9-month injectable regimen through 132 weeks, according to long-term data from the STREAM 2 trial.

Bedaquiline-containing regimens show sustained benefit in rifampicin-resistant TB

16 Oct 2024
Sexual dysfunction prevalent in women with PAH

Sexual dysfunction prevalent in women with PAH

15 Oct 2024

Many women with pulmonary arterial hypertension (PAH) with a mild functional impairment suffer from sexual dysfunction, a recent study claims.

Sexual dysfunction prevalent in women with PAH

15 Oct 2024
Music a perioperative aide for lung cancer patients?

Music a perioperative aide for lung cancer patients?

15 Oct 2024 bởiAudrey Abella

Individuals with resectable stage IA to IIIB non-small cell lung cancer (NSCLC) who plan to receive minimally invasive lung surgery may benefit from intensity-based personalized music therapy (IBP-MT) suggests the phase II Music of Lung Health II study.

Music a perioperative aide for lung cancer patients?

15 Oct 2024
Clozapine-treated patients with schizophrenia at risk for ileus, pneumonia

Clozapine-treated patients with schizophrenia at risk for ileus, pneumonia

10 Oct 2024

Ileus and pneumonia occur more frequently than previously reported among individuals with schizophrenia treated with clozapine, reveals a recent study, noting that such conditions also contribute to increased mortality.

Clozapine-treated patients with schizophrenia at risk for ileus, pneumonia

10 Oct 2024
Pulmonary arterial hypertension outcomes better with early therapy augmentation with selexipag

Pulmonary arterial hypertension outcomes better with early therapy augmentation with selexipag

04 Oct 2024 bởiJairia Dela Cruz

In the treatment of patients with pulmonary arterial hypertension, adding selexipag as a third medication sooner rather than later is crucial to help prevent hospitalization and disease progression, as suggested in an emulated target trial.

Pulmonary arterial hypertension outcomes better with early therapy augmentation with selexipag

04 Oct 2024